BACKGROUND AND AIMS: Current treatment with nucleos(t)ide analogs (NUCs) safely controls the replication of hepatitis B virus (HBV) and improves prognosis in patients with HBV. However, the inability to completely clear HBV is problematic, and nov...

IFN-λ3 as a host immune response in acute hepatitis E virus infection

Kazumoto Murata Jong-Hon Kang Shigeo Nagashima Takeshi Matsui Yoshiyasu Karino Yoshiya Yamamoto Tomofumi Atarashi Masatsugu Oohara Minoru Uebayashi Hidekatsu Sakata Keiji Matsubayashi Kazuaki Takahashi Masahiro Arai Shunji Mishiro Masaya Sugiyama Masashi Mizokami Hiroaki Okamoto

Cytokine 125 154816-154816 2020年1月 [査読有り]

Background and aim: Hepatitis E virus (HEV) is mainly transmitted orally, either waterborne or zoonotic foodbome. Intestinal viruses such as rotavirus are known to induce type III interferon (IFN) in the gastrointestinal (GI) tract where type III ...

Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection

Kazumoto Murata Mai Asano Akihiro Matsumoto Masaya Sugiyama Nao Nishida Eiji Tanaka Taisuke Inoue Minoru Sakamoto Nobuyuki Enomoto Takayoshi Shirasaki Masao Honda Shuichi Kaneko Hiroyuki Gatanaga Shinichi Oka Yuki I Kawamura Taeko Dohi Yasutaka Shuno Hideaki Yano Masashi Mizokami

Gut 67(2) 362-371 2018年2月 [査読有り]

<sec><title>Objective</title>The clinical significance of polymorphisms in the interleukin-28B gene encoding interferon (IFN)-λ3, which has antiviral effects, is known in chronic HCV but not in HBV infection. Thus, we measured IFN-λ3 levels in pat...

Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients

Kazumoto Murata Masaya Sugiyama Tatsuji Kimura Sachiyo Yoshio Tatsuya Kanto Ikue Kirikae Hiroaki Saito Yoshihiko Aoki Satoshi Hiramine Teppei Matsui Kiyoaki Ito Masaaki Korenaga Masatoshi Imamura Naohiko Masaki Masashi Mizokami

Journal of Gastroenterology 49(1) 126-137 2014年1月 [査読有り]

Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity

ZEISSIG S

Nat Med 18(7) 1060-1068 2012年7月 [査読有り]

もっとみる

MISC

12 3 4 5 >

胃内視鏡的粘膜下層剥離術(ESD)前夜vonoprazan投与におけるESD時胃液pHと臨床経過

須藤大輔吉田昌大竹孝明一石英一郎佐藤貴一村田一素鈴木裕高後裕

潰瘍 47 2020年

B型肝炎治療 2018 核酸アナログ製剤によるIFN‐λ誘導とそれを標的としたB型肝炎治療薬の探索

村田一素前仲勝実溝上雅史

Mebio 35(1) 80‐87-87 2018年1月

●核酸アナログ製剤はB型肝炎ウイルスの逆転写酵素を阻害するが、アデホビル、テノホビルには、インターフェロン(interferon;IFN)-λ3を誘導するという追加効果がある。●誘導されたIFN-λ3は、HBs抗原産生を抑制し、ISG(IFN-stimulated genes;IFN誘導遺伝子)を誘導する。●アデホビル、テノホビルの単独療法によるHBs抗原もしくはdrug-offはまれであるので、さらに強力にIFN-λ3を誘導する薬剤などIFN-λ3を標的とした新規治療法の開発が期待される...

HLA-DRB1-DQB1 haplotypes and BTNL2 gene associate with response to a hepatitis B vaccine

Nao Nishida Masaya Sugiyama Hiromi Sawai Sohji Nishina Aiko Sakai Keisuke Kakisaka Keisuke Hino Ryo Sumazaki Yasuhiro Takikawa Kazumoto Murata Tatsuo Kanda Osamu Yokosuka Katsushi Tokunaga Masashi Mizokami

HEPATOLOGY 66 796A-797A 2017年10月

Effects of interferon-free treatment on serum cholesterol levels are different between the two sofosbuvir-based regimens in chronic HCV-infected patients

Naohiko Masaki Masaaki Korenaga Mikio Yanase Yuichi Nozaki Shintaro Mikami Yoshihiko Aoki Masatoshi Imamura Kazumoto Murata Tatsuya Kanto Masashi Mizokami

HEPATOLOGY 64 981A-981A 2016年10月

Induction of IFN-lambda 3 as an Additional Effect of Nucleotide, Not Nucleoside, Analogs: A New Potential Target for Hepatitis B Virus Infection

Kazumoto Murata Akihiro Matsumoto Masaya Sugiyama Eiji Tanaka Taisuke Inoue Minoru Sakamoto Nobuyuki Enomoto Masao Honda Shuichi Kaneko Hiroyuki Gatanaga Shinichi Oka Masashi Mizokami

HEPATOLOGY 64 306A-306A 2016年10月